SOURCE: Prana Biotechnology

December 05, 2007 14:13 ET

Prana Biotechnology to Co-Host Expert Panel Discussion

Panel to Address "Exploring Surrogate Markers for Drug Development in Alzheimer's Disease and Dementia: The Near Horizon"

MELBOURNE, AUSTRALIA--(Marketwire - December 5, 2007) - Prana Biotechnology Limited (NASDAQ: PRAN) (ASX: PBT), a biopharmaceutical company focused on the research and development of treatments for neurodegenerative disorders, today announced that the Company will host a panel discussion, in conjunction with Rodman and Renshaw, Oxford BioScience Partners, and other distinguished medical and scientific experts, at Oxford BioScience Partners, at 9:00 a.m. on December 10, 2007.

The panel, titled "Exploring Surrogate Markers for Drug Development in Alzheimer's Disease and Dementia: The Near Horizon," will offer an informative discussion on the progress and challenges of CNS drug discovery for dementia and the potential of surrogate markers (biomarkers, imaging, and genetic markers) in the drug discovery process for neurocognitive diseases. Speakers include Dr. Rudy Tanzi, Co-Founding Scientist of Prana, Dr. Steven Targum, Chief Medical Advisor to Prana, and Dr. Robert Green, Professor of Neurology and Co-Director of the Alzheimer's Disease Clinical & Research Program at Boston University.

Prana's treatments for Alzheimer's and other neurodegenerative diseases target the interaction between the beta-amyloid protein and metals in the brain. Prana's proprietary lead compound, PBT2, is currently in a Phase IIa clinical trial for patients with early Alzheimer's disease. The trial is on track to be completed by the end of 2007. As part of this trial, measurable outcomes will be CSF and plasma biomarkers.

Mr. Geoffrey Kempler, Prana's CEO, commented, "This clinical trial is assessing the safety and tolerability of PBT2 as a treatment for Azheimer's Disease. It also will provide valuable information on the movement of surrogate biomarkers, validating the further development and commercial significance of PBT2."

The panel discussion will take place at Oxford BioScience Partners, in Boston. Seating is very limited, but a webcast will be available for those who can not attend, with details as follows:

                        Webcast
          http://www.vcall.com/IC/CEPage.asp?ID=123536
          Webcast Replay Available Until: 12/10/2008
      Dial In: (Toll Free) 877-407-0778, (International) 201-689-8565
      Replay: (Toll Free) 877-660-6853, (International) 201-612-7415
      Replay Pass codes: Account # 286, Conference ID # 263913

For further details, please visit the Prana website at www.pranabio.com, or contact Rodman and Renshaw, at www.rodmanandrenshaw.com


About Prana Biotechnology Limited

Prana Biotechnology was established to commercialize research into Alzheimer's disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including The University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, contributed to the discovery of Prana's technology.

For further information, please visit our website at www.pranabio.com.

Contact Information